Objective
Diabetes mellitus is common in U.S. nursing homes (NH), and the
mainstay treatment, metformin, has U.S. Food and Drug Administration (FDA)
boxed warnings indicating safety concerns in those with advanced age, heart
failure, or renal disease. Little is known about treatment selection in this
setting, especially for metformin. We quantified the determinants of
initiating sulfonylureas over metformin with the aim of understanding the
impact of FDA-labeled boxed warnings in older NH residents.
Design and Setting
National retrospective cohort in U.S. NHs.
Participants
Long-stay NH residents age ≥65 years who initiated metformin
or sulfonylurea monotherapy following a period of ≥6 months with no
glucose-lowering treatment use between 2008 and 2010 (N=7,295).
Measurements
Measures of patient characteristics were obtained from linked
national Minimum Data Set assessments; Online Survey, Certification and
Reporting (OSCAR) records; and Medicare claims. Odds ratios (ORs) comparing
patient characteristics and treatment initiation were estimated using
univariable and multivariable multilevel logistic regression models with NH
random intercepts.
Results
Of the 7,295 residents in the study population, 3,066 (42%)
initiated metformin and 4,229 (58%) initiated a sulfonylurea. In
multivariable analysis, several factors were associated with sulfonylurea
initiation over metformin initiation, including heart failure (OR =
1.2, 95% confidence interval (CI) 1.1–1.4) and renal disease
(OR=2.1, 95%CI 1.7–2.5). Compared to those aged 65
to <75 years, residents 75 to <85 (OR=1.3,
95%CI 1.2–1.5), 85 to <95 (OR=2.0,
95%CI 1.7–2.3), and ≥95 (OR=4.3,
95%CI 3.2–5.8) years old were more likely to initiate
sulfonylureas over metformin.
Conclusions
In response to FDA warnings, providers initiated NH residents on a
drug class with a known, common adverse event (hypoglycemia with
sulfonylureas) over one with tenuous evidence of a rare adverse event
(lactic acidosis with metformin).